Larvol Delta - Safety-and-tolerability-of-nonneutralizing-adrenomedullin-antibody-adrecizumab-HAM8101-in-septic-shock-patients-the-AdrenOSS2-phase-2a-biomarkerguided-trial

enibarcimab (HAM 8101) - Adrenomed

http://www.ncbi.nlm.nih.gov/pubmed/34605947

Oct 5, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next